Here are three things to know
1. The drug, Steglatro, is a SGLT2 inhibitor, which works by causing patients with Type 2 diabetes to rid glucose through their urine.
2. The oral drug enters the market as a competitor to AstraZeneca’s Farxiga, Johnson & Johnson’s Invokana and Eli Lilly and Boehringer Ingelheim’s Jardiance.
3. The FDA granted Steglatro approval as both a single-therapy or a fixed-dose combination therapy with Merck’s already-approved diabetes drug Januvia or metformin, which is an older generic version of a diabetes drug.
More articles on supply chain:
6 must-reads for supply chain leaders this week
France officials fine J&J $30M for allegedly restricting access to generic versions of its pain patch
Pfizer authorizes $10B share buyback
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
